Roche's (OTCQX:RHHBY) Genentech unit has received FDA approval for its drug Susvimo 100 mg/mL injection for the treatment of ...

Roche's Genentech unit has won FDA approval for Susvimo, an implant for eyesight-robbing disease wet age-related macular degeneration (AMD) that gives patients an alternative to regular injections ...

Roche’s Genentech unit has said will reintroduce its Susvimo implant for eyesight-robbing disease age-related macular degeneration (AMD), which was withdrawn from sale in 2022 due to ...

In other recent news, Genentech, a part of Roche Group, announced the FDA's approval of Susvimo for the treatment of diabetic macular edema (DME). The approval follows positive results from the ...

San Francisco, California–based Genentech, has potent antitumor activity. More than half the patients with advanced and inoperable skin cancer treated with GDC-0449 responded to treatment (New Engl.

A four-year battle over one of the most ubiquitous patents in biotech ended with the US Patent and Trademark Office (USPTO) coming down on Genentech's side. The decision, reached in February ...